26 February 2024 ORYZON reports financial results and corporate update for quarter ended December 31, 2023
19 January 2024 ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
5 January 2024 ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD)
21 November 2023 ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million
7 November 2023 ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)
27 October 2023 ORYZON reports financial results and corporate updates for quarter ended September 30, 2023